Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus GP induction chemotherapy, cisplatin chemoradiotherapy, and capecitabine adjuvant chemotherapy for high-risk locally advanced nasopharyngeal carcinoma
ChiCTR2200062900Phase 2Recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Aug 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, gemcitabine, cisplatin and capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Cancer Center of Guangzhou Medical University. Primary endpoint: 3-year failure-free survival. Started Aug 2022; status: recruiting.
02
Drugs
camrelizumabgemcitabinecisplatincapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2200062900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062900.